Revium Rx.: securities offering

Form: S-1
Filed: Feb 14, 2025, 8:51 am ET
Importance: Notable
Accession: 0001213900-25-013823
Document: S-1
Exhibit 4.1: Form of the IPO warrants to be issued by the company in this offering
Exhibit 4.2: Form of investor warrants issued by the company in the first private placement…
Exhibit 4.3: Form of investor warrants issued by the company in the second private placement
Exhibit 10.1: License and research agreement between yissum research development company of…
Exhibit 10.2: First amendment to the license and research agreement yissum research…
Exhibit 10.3: Second amendment to the license and research agreement yissum research…
Exhibit 10.4: License and research agreement between yissum research development company of…
Exhibit 10.5: First amendment to the license and research agreement yissum research…
Exhibit 10.6: Research and option agreement effective as of October 25, 2023 (arb)
Exhibit 10.7: Research and option agreement between yissum research development company of…
Exhibit 10.8: First amendment to the research and option agreement between yissum research…
Exhibit 10.9: Second amendment to the research and option agreement between yissum research…
Exhibit 10.10: Form of subscription agreement executed by the registrant and subscribers in…
Exhibit 10.11: Form of subscription agreement executed by the registrant and subscribers in…
Exhibit 10.13: Employment agreement dated as of February 1, 2024 between inna martin and…
Exhibit 10.14: Consulting agreement dated as of dec 15, 2020 between inna martin and Revium…
Exhibit 10.15: Amendment to consulting agreement June 29, 2023 between inna martin and Revium…
Exhibit 10.16: Amendment to consulting agreement dated December 24, 2024 between inna martin…
Exhibit 10.17: Employment agreement dated as of December 18, 2024 between david akunis and…

Not explained yet; the original is on EDGAR.

Securities offering

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

GeoVax Labs GOVX public float $14M, Jun 30, 2025
ProPhase Labs PRPH public float $15M, Jun 30, 2025
Cellectar Biosciences CLRB public float $13M, Jun 30, 2025
Cocrystal Pharma COCP public float $12M, Jun 30, 2025
Marker Therapeutics MRKR public float $17M, Jun 30, 2025

Get an email when Revium Rx. files

Similar companies